Inflammation and diabetes-accelerated atherosclerosis: Myeloid cell mediators

Trends in Endocrinology and Metabolism

Volumn 24, Issue 3, 2013, Pages 137-144

  Kanter, Jenny E ^a   Bornfeldt, Karin E ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acyl CoA synthetase; Arachidonic acid; Eicosanoids; Macrophage; Monocyte

Indexed keywords

ACETYL COENZYME A SYNTHETASE; ACETYL COENZYME A SYNTHETASE 1; ARACHIDONIC ACID; CHEMOKINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; CYTOKINE; GAMMA INTERFERON; GLUCOSE; ICOSANOID; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE DERIVATIVE; LIPOPOLYSACCHARIDE; LONG CHAIN FATTY ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E SYNTHASE 1; STREPTOZOCIN; THROMBOXANE DERIVATIVE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; BONE MARROW CELL; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DISEASE MODEL; DYSLIPIDEMIA; ENZYME INDUCTION; ENZYME INHIBITION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INNATE IMMUNITY; INS2 GENE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; MACROPHAGE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT ATTITUDE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; STREPTOZOCIN DIABETES;

ANIMALS; ARACHIDONIC ACID; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; EICOSANOIDS; HUMANS; INFLAMMATION; MACROPHAGES; MICE; MONOCYTES; MYELOID CELLS;

EID: 84875260543     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.10.002     Document Type: Review

References (57)

1. Bornfeldt K.E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011, 14:575-585.
2. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
3. Kanter J.E., et al. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E715-E724.
4. Grundy S.M. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 2012, 59:635-643.
5. Hu F.B., et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
6. Renard C.B., et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest. 2004, 114:659-668.
7. Bradshaw E.M., et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J. Immunol. 2009, 183:4432-4439.
8. Padmos R.C., et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes 2008, 57:2768-2773.
9. Jialal I., Kaur H. The role of toll-like receptors in diabetes-induced inflammation: Implications for vascular complications. Curr. Diab. Rep. 2012, 12:172-179.
10. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:986-1000.
11. Sabido E., et al. Targeted proteomics of the eicosanoid biosynthetic pathway completes an integrated genomics-proteomics-metabolomics picture of cellular metabolism. Mol. Cell. Proteomics 2012, 11. M111.014746.
12. Buczynski M.W., et al. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 2009, 50:1015-1038.
13. Balgoma D., et al. Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids. J. Immunol. 2010, 184:3857-3865.
14. Díaz-Muñoz M.D., et al. Involvement of PGE2 and the cAMP signalling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS-activated macrophages. Biochem. J. 2012, 443:451-461.
15. Kihara Y., et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21807-21812.
16. Natarajan R., Nadler J.L. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1542-1548.
17. Lo C.J. Upregulation of cyclooxygenase-II gene and PGE2 production of peritoneal macrophages in diabetic rats. J. Surg. Res. 2005, 125:121-127.
18. Beyan H., et al. Monocyte gene-expression profiles associated with childhood-onset type 1 diabetes and disease risk: a study of identical twins. Diabetes 2010, 59:1751-1755.
19. Zhou Y.J., et al. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability. Biochem. Biophys. Res. Commun. 2007, 363:30-36.
20. Minami M., et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J. Biol. Chem. 2008, 283:9692-9703.
21. Babaev V.R., et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab. 2008, 8:492-501.
22. Kim S.H., et al. Distinct protein kinase A anchoring proteins direct prostaglandin E2 modulation of Toll-like receptor signaling in alveolar macrophages. J. Biol. Chem. 2011, 286:8875-8883.
23. Zaslona Z., et al. Prostaglandin E2 restrains macrophage maturation via E prostanoid receptor 2/protein kinase A signaling. Blood 2012, 119:2358-2367.
24. Hertz A.L., et al. Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21978-21983.
25. Ellis J.M., et al. Acyl-coenzyme A synthetases in metabolic control. Curr. Opin. Lipidol. 2010, 21:212-217.
26. Ellis J.M., et al. Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol. Cell. Biol. 2011, 31:1252-1262.
27. Li L.O., et al. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J. Biol. Chem. 2009, 284:27816-27826.
28. Ellis J.M., et al. Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab. 2010, 12:53-64.
29. Kanter J.E., et al. Acyl-CoA synthetase 1 is required for oleate and linoleate mediated inhibition of cholesterol efflux through ATP-binding cassette transporter A1 in macrophages. Biochim. Biophys. Acta 2012, 1821:358-364.
30. Kanter J.E., et al. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques?. Circ. Res. 2007, 100:769-781.
31. Zhang S.H., et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471.
32. Plump A.S., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
33. Ishibashi S., et al. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 1994, 93:1885-1893.
34. Hasty A.H., et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem. 2001, 276:37402-37408.
35. -/- mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease. J. Lipid Res. 2011, 52:1483-1493.
36. -/- mice heterozygous for the insulin receptor and the insulin receptor substrate-1. Arterioscler. Thromb. Vasc. Biol. 2012, 32:247-256.
37. Félétou M., et al. TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis. Adv. Pharmacol. 2010, 60:85-106.
38. Makowski L., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 2001, 7:699-705.
39. Kazemi M.R., et al. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1220-1224.
40. Makowski L., et al. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 2005, 280:12888-12895.
41. Furuhashi M., Hotamisligil G.S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 2008, 7:489-503.
42. Babaev V.R., et al. Macrophage Mal1 deficiency suppresses atherosclerosis in low-density lipoprotein receptor-null mice by activating peroxisome proliferator-activated receptor-γ-regulated genes. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1283-1290.
43. Peeters W., et al. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur. Heart J. 2011, 32:1758-1768.
44. Agardh H.E., et al. Expression of fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosis. J. Intern. Med. 2011, 269:200-210.
45. Furuhashi M., et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS ONE 2011, 6:e27356.
46. Furuhashi M., et al. Lipid chaperones and metabolic inflammation. Int. J. Inflam. 2011, 2011:642612.
47. Lewis P., et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 2007, 115:2178-2187.
48. Torzewski M., et al. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:850-857.
49. Ramasamy R., Goldberg I.J. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ. Res. 2010, 106:1449-1458.
50. Vikramadithyan R.K., et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 2005, 115:2434-2443.
51. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1805-1813.
52. Schoonjans K., et al. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur. J. Biochem. 1993, 216:615-622.
53. Martin G., et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem. 1997, 272:28210-28217.
54. 2 release from human arterial smooth muscle cells. J. Lipid Res. 2011, 52:782-793.
55. Johnson C.O., et al. Common variation in fatty acid genes and resuscitation from sudden cardiac arrest. Circ. Cardiovasc. Genet. 2012, 5:422-429.
56. Furuhashi M., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
57. Leuschner F., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 2011, 29:1005-1010.